Boryeong Begins First Supply of "Alimta" to Taiwan's Lotus... Accelerates Global CDMO Expansion

Expanding Global Presence with a Focus on Cytotoxic Anticancer Drugs

Boryeong announced on May 18 that it has begun supplying the anticancer drug Alimta (active ingredient: pemetrexed) to the Taiwanese pharmaceutical company Lotus Pharmaceuticals.

Participants are taking photos at the 'Alimta Global CDMO Supply Launch' commemorative event held at Boryeong Yesan Campus on the 18th. Photo by Boryeong

This supply is based on a CDMO (Contract Development and Manufacturing Organization) agreement signed by the two companies in 2024. The drug is produced at Boryeong's Yesan Campus, which has obtained EU-GMP certification. With this initiative, Boryeong plans to increase its global supply of cytotoxic anticancer drugs and accelerate the expansion of its CDMO business.

Boryeong has successively acquired the businesses of global original anticancer brands such as Gemzar, Alimta, and Taxotere, internalizing related technologies by transferring them to its own production facilities. In particular, for Alimta, the company improved product competitiveness and profitability by converting the formulation from powder to liquid. Based on these formulation improvement capabilities and its quality control system, Boryeong aims to establish a high value-added CDMO business model that goes beyond simple contract manufacturing.

Recently, the global market has faced serious shortages in the supply of essential cytotoxic anticancer drugs such as cisplatin and carboplatin, as well as delays in treatment, due to production halts at major sites and instability in raw material procurement. Accordingly, the World Health Organization (WHO) and health authorities in each country have designated cytotoxic anticancer drugs as essential medicines, emphasizing the establishment of stable supply chains as a key priority.

Sungjin Kim, Chief Strategy Officer (CSO) of Boryeong, stated, "Amid global supply chain instability, the ability to ensure stable production and quality control of pharmaceuticals is a core competitive advantage. Based on our world-class infrastructure, we aim to become a trusted supply partner in the market and continuously expand our role within the global pharmaceutical supply chain."

This content was produced with the assistance of AI translation services.